Avastin Patient Assistance program

Genentech BioOncology is pleased to announce the Avastin Patient Assistance program, a new program that expands our current portfolio of patient assistance services. The Avastin Patient Assistance program was developed in response to concerns about increased costs associated with the higher doses of the new indications FDA approved in 2006. By limiting the overall annual cost of Avastin, the program can help oncologists and patients pursue clinically appropriate on-label treatment without concern about additional costs.

How the Avastin Patient Assistance program works

The Avastin Patient Assistance program provides an opportunity for physicians and eligible on-label patients who reach an annual dosage of 10,000* mg to receive free Avastin from Genentech for the remainder of the 12 month period.

• Participation in the program is voluntary. The treating oncologist identifies eligible patients for enrollment in the program.
• The treatment year is measured for each patient independently and begins with the patient's first infusion.
• At the end of the patient's first 12 months of therapy, the patient and/or payer resumes financial responsibility until the 10,000-mg limit is reached in the next 12 months.
• Patients are eligible to receive free Avastin only if they are treated by the same provider throughout the period when the 10,000 mg of Avastin accrues. Patients who transfer providers while receiving free drug under the program will only be eligible if the new location is within the original provider's organization.

Patient Eligibility

• The Avastin Patient Assistance program is open to all patients receiving Avastin (regardless of insurance coverage) with a household adjusted gross income up to $100,000
• Patients must be receiving Avastin for an FDA-approved indication
• Patients must reach the annual dosage of 10,000 mg of Avastin from a single provider or provider organization

Please direct requests for more specific information on eligibility to:

* The 10,000-mg threshold is based on the approximate yearly dosage of Avastin treatment in an average 75-kg patient, based on the initial metastatic colorectal cancer indication.

The Avastin Patient Assistance program, at its sole and absolute discretion, reserves the right to modify or discontinue the program at any time, and to verify the accuracy of the information submitted.